Clinical Trial Update: Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children [Phase 4]

View source ↗

Summary

A Phase 4 safety and tolerability study of Adhansia XR extended-release capsules in children with ADHD was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Adhansia XR (methylphenidate extended-release)

Snippet

Sponsor: Purdue Pharma LP | Conditions: Attention Deficit/Hyperactivity Disorder | Phase 4 | Status: TERMINATED | Results posted: 2023-08-22